1-8 of 8
Myeloid Neoplasia/Acute Myeloid Leukemia
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeting scavenger receptor class B type 1 with a bioinspired ligand induces apoptosis or ferroptosis in AML

Open Access
Adam Y. Lin, Jonathan S. Rink, Eva Yang, Sara Small, Jessica J. Gerber, Taylor J. Zak, Jessica Altman, Yasmin Abaza, Leonidas C. Platanias, Leo I. Gordon, C. Shad Thaxton
Journal: Blood Neoplasia
Blood Neoplasia (2025) 2 (4): 100122.
https://doi.org/10.1016/j.bneo.2025.100122
Published: 2025
Includes: Supplemental data
Journal Articles

Juvenile myelomonocytic leukemia stem cells are sensitive to NK cell–mediated lysis and express targetable antigens

Open Access
Shannalee Martinez, Vladimir V. Senyukov, Suheyla Hasgur, Arianexys Aquino-López, Peter D. Emanuel, Y. Lucy Liu, Elliot Stieglitz, Gregory Behbehani, Amanda R. Campbell, Dean A. Lee
Journal: Blood Neoplasia
Blood Neoplasia (2025) 2 (4): 100135.
https://doi.org/10.1016/j.bneo.2025.100135
Published: 2025
Includes: Supplemental data
Journal Articles

Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML

Open Access
Andrew D Zale, Venkata Preetam Sandeep Kaduluri, Jonathan A Webster, Mark J Levis, Ivana Gojo, Amy E DeZern, Gabriel Ghiaur, Lukasz P Gondek, William Brian Dalton, Theodoros Karantanos, Tania Jain, Gabrielle T Prince, Richard J Jones, B. Douglas Smith, Alexander J Ambinder
Journal: Blood Neoplasia
Blood Neoplasia (2025) 2 (4): 100133.
https://doi.org/10.1016/j.bneo.2025.100133
Published: 2025
Includes: Supplemental data
Journal Articles

Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1

Open Access
Courtney D. DiNardo, Wei-Ying Jen, Guillermo Montalban-Bravo, Xuemei Wang, Sanam Loghavi, Sravanthi Lavu, Nicholas J. Short, Kelly Chien, Ghayas C. Issa, Naveen Pemmaraju, Musa Yilmaz, Michael Andreeff, Gautam Borthakur, Tapan M. Kadia, Naval G. Daver, Guillermo Garcia-Manero, Christopher P. Mill, Xiaoping Su, Warren Fiskus, Kapil N. Bhalla
Journal: Blood Neoplasia
Blood Neoplasia (2025) 2 (4): 100145.
https://doi.org/10.1016/j.bneo.2025.100145
Published: 2025
Journal Articles

Posttranscriptional activity of eIF4E contributes to HoxA9-driven leukemogenesis

Open Access
Fang Zhou, Biljana Culjkovic-Kraljacic, Christian Bach, Li Feng, Yuta Mishima, Katherine L. B. Borden, Daniel G. Tenen
Journal: Blood Neoplasia
Blood Neoplasia (2025) 2 (4): 100132.
https://doi.org/10.1016/j.bneo.2025.100132
Published: 2025
Includes: Supplemental data
Journal Articles

Three-year follow-up of low-dose, early-start gilteritinib maintenance in posttransplant patients with R/R FLT3 mut AML

Open Access
Clinical Trials & Observations
Toshiki Terao, Ken-ichi Matsuoka, Takumi Kondo, Yoshinobu Maeda
Journal: Blood Neoplasia
Blood Neoplasia (2025) 2 (4): 100141.
https://doi.org/10.1016/j.bneo.2025.100141
Published: 2025
Journal Articles

SRSF2 mutations in CCUS, MDS and AML: a cross-entity study

Open Access
Sandra Huber, Sarah Ochmann, Stephan Hutter, Veronika Ecker, Manja Meggendorfer, Gregor Hoermann, Torsten Haferlach, Claudia Haferlach, Isolde Summerer
Journal: Blood Neoplasia
Blood Neoplasia (2025) 2 (4): 100144.
https://doi.org/10.1016/j.bneo.2025.100144
Published: 2025
Includes: Supplemental data
Journal Articles

Targeting CDK9 inhibits the growth of KMT2A-rearranged infant leukemia and demonstrates synergy with menin inhibition

Open Access
Ritul Sharma, Chunfen Zhang, Ravi Shah, Melanie M. Frigault, Amy J. Johnson, David Spencer Mangum, Luke D. Maese, Norman J. Lacayo, Aru Narendran
Journal: Blood Neoplasia
Blood Neoplasia (2025) 2 (4): 100148.
https://doi.org/10.1016/j.bneo.2025.100148
Published: 2025
Includes: Supplemental data